BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 34478654)

  • 1. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
    Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
    Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
    Haeussler M; Concordet JP
    J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods for Measuring CRISPR/Cas9 DNA Cleavage in Cells.
    Cromwell CR; Jovel J; Hubbard BP
    Methods Mol Biol; 2021; 2162():197-213. PubMed ID: 32926384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
    Tycko J; Myer VE; Hsu PD
    Mol Cell; 2016 Aug; 63(3):355-70. PubMed ID: 27494557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
    Moreb EA; Hutmacher M; Lynch MD
    CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric DNA-RNA Guide RNA Designs.
    Lu S; Zhang Y; Yin H
    Methods Mol Biol; 2021; 2162():79-85. PubMed ID: 32926379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Assays for Comparing the Specificity of First- and Next-Generation CRISPR/Cas9 Systems.
    Cromwell CR; Hubbard BP
    Methods Mol Biol; 2021; 2162():215-232. PubMed ID: 32926385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a.
    Swarts DC; van der Oost J; Jinek M
    Mol Cell; 2017 Apr; 66(2):221-233.e4. PubMed ID: 28431230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Disruption Using Chemically Modified CRISPR-Cpf1 RNA.
    McMahon MA; Rahdar M
    Methods Mol Biol; 2021; 2162():49-60. PubMed ID: 32926377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
    Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
    Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridge Helix of Cas9 Modulates Target DNA Cleavage and Mismatch Tolerance.
    Babu K; Amrani N; Jiang W; Yogesha SD; Nguyen R; Qin PZ; Rajan R
    Biochemistry; 2019 Apr; 58(14):1905-1917. PubMed ID: 30916546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The initiation, propagation and dynamics of CRISPR-SpyCas9 R-loop complex.
    Zeng Y; Cui Y; Zhang Y; Zhang Y; Liang M; Chen H; Lan J; Song G; Lou J
    Nucleic Acids Res; 2018 Jan; 46(1):350-361. PubMed ID: 29145633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
    Zheng W
    Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for mismatch surveillance by CRISPR-Cas9.
    Bravo JPK; Liu MS; Hibshman GN; Dangerfield TL; Jung K; McCool RS; Johnson KA; Taylor DW
    Nature; 2022 Mar; 603(7900):343-347. PubMed ID: 35236982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
    Swartjes T; Staals RHJ; van der Oost J
    Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating Cas9 activity for precision gene editing.
    Uslu M; Siyah P; Harvey AJ; Kocabaş F
    Prog Mol Biol Transl Sci; 2021; 181():89-127. PubMed ID: 34127203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.
    Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM
    Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.